Maze Therapeutics Stock Falls Despite Strong Phase 2 Kidney Drug Data For MZE829

• Maze Therapeutics stock is among today’s weakest performers. What’s behind MAZE decline?AMKD is a type of kidney disease caused by variants (changes) in the APOL1 (apolipoprotein L1) gene.The trial results showed a 35.6% mean reduction in urinary albumin-to-creatinine ratio (uACR) among broad AMKD patients treated with MZE829, with 50% of patients achieving a reduction of over 30%.uACR measures albumin (a blood protein) and creatinine (a waste product) in a urine sample to assess kidney function. A healt ...